Ulcerative Colitis (UC) Clinical Trial
Official title:
German Spondyloarthritis Inception Cohort
The German Spondyloarthritis Inception cohort (GESPIC) was started 2000 as a prospective, longitudinal, multicentre, nationwide study in Germany on patients with early SpA including ankylosing spondylitis (AS, also known as radiographic axial spondyloarthritis) and non-radiographic axial SpA. The objectives of GESPIC are to learn about the course of SpA during the very early stage of the disease, to appropriately assess the outcome including radiographic progression of patients after several years of follow-up, to identify outcome predictors, to assess quality of life, function, and costs (direct and indirect costs). GESPIC has been recently expanded to recruit patients with other forms of SpA / conditions associated with SpA: acute anterior uveitis, Crohn's disease as well as with psoriasis / axial psoriatic arthritis.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02819635 -
A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT05960864 -
Chinese Spondyloarthritis Inception Cohort (CESPIC)
|
||
| Not yet recruiting |
NCT05316220 -
A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis
|
Phase 3 | |
| Completed |
NCT02345733 -
Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis
|
Phase 4 | |
| Terminated |
NCT02217722 -
Use of the Ulcerative Colitis Diet for Induction of Remission
|
N/A | |
| Completed |
NCT02778464 -
Faecal Calprotectin as a Potential Non-invasive Inflammatory Marker in Pregnancy and Inflammatory Bowel Disease
|
||
| Completed |
NCT01971814 -
Early Serum Infliximab Levels in Severe Ulcerative Colitis.
|
Phase 1 | |
| Completed |
NCT03223012 -
Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service
|
||
| Active, not recruiting |
NCT03456206 -
Chronic Inflammatory Disease, Lifestyle and Risk of Disease
|
||
| Completed |
NCT04254783 -
A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
|
Phase 1 | |
| Completed |
NCT03398148 -
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT02087878 -
A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel Disease, Who Have Been Treated With Adalimumab and Who Developed Hepatosplenic T-Cell Lymphoma
|
||
| Completed |
NCT02065622 -
Study to Evaluate the Safety and Efficacy of Two Adalimumab Dosing Regimens in Subjects With Moderate to Severe Ulcerative Colitis
|
Phase 3 | |
| Completed |
NCT03695185 -
A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy
|
Phase 2 | |
| Completed |
NCT02108821 -
Fecal Microbiota Transplantation in Pediatric Patients
|
Phase 1 | |
| Terminated |
NCT03758443 -
Efficacy & Safety of TD-1473 in Ulcerative Colitis
|
Phase 2/Phase 3 | |
| Completed |
NCT01364896 -
Anal Human Papillomavirus in Inflammatory Bowel Disease Study
|
||
| Terminated |
NCT03920254 -
TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05377580 -
A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis
|
Phase 2 | |
| Recruiting |
NCT03609905 -
Adipose Mesenchymal Stem Cells (AMSC) for Treatment of Ulcerative Colitis
|
Phase 1/Phase 2 |